Catalys Pacific — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Mineralys Therapeuticsmineralystx.cominNASDAQ: MLYSJun 2022SEC filinghigh confidence
Clinical-stage biopharmaceutical company committed to developing best-in-class novel therapy for hypertension treatment.
BiotechRadnor, US
Adam Levy(Executive Officer)Srinivas Akkaraju(Director)Alexander Asam(Director)
BoardOlivier Litzka(Director)Derek DiRocco(Director)
Board seatTakeshi TakahashiBrian Taylor Slingsby· per SEC Form D · $118M raise · filed Jun 2022
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.